High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol

Brice, P.;Simon, D;Bouabdallah, R.;Belanger, C;Solal-Celigny, P.;et.al.
(2000) Annals of Oncology — Vol. 11, n° 12, p. 1585-1590 (2000)

Files

No attached file found for this publication.

Details

Authors
  • Brice, P.
    Author
  • Simon, D
    Author
  • Bouabdallah, R.
    Author
  • Belanger, C
    Author
  • Solal-Celigny, P.
    Author
Show more
Abstract
Background: Among the 566 patients with follicular lymphomas (FL) included in the GELF 86 prospective trials from October 1986 to September 1995, 372 with progressive/relapsing disease were analyzed retrospectively to identify prognostic factors at first relapse. Patients and methods: For progressive FL, patients received mono- (22%) or polychemotherapy (78%) followed by high-dose therapy (HDT) with ASCT for 83 patients (22%). The median time to progression from initial treatment was 23 months (range 3-102 months) and 24% of documented patients (52 of 217) had histological transformation (HT). Salvage therapy produced an overall response in 64% of patients and the five-year survival from progression was 42%. Results: For patients who underwent HDT with ASCT compared to standard treatment, five-year freedom from second failure was at 42% vs. 16% (P = 0.0001) and five-year survival was 58% vs. 38% (P = 0.0005), respectively. The benefit of HDT and ASCT remained if we consider only patients less than 65 years (five-year survival at 60% vs. 40%; P = 0.001). Multivariate analysis of parameters significant according to univariate analysis found that no ASCT at first progression, age at relapse > 50 years, progression on-therapy were adversely significant on survival. Conclusions: HDT with ASCT compared to standard treatment prolonged remission and survival after first progression of FL patients.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Brice, P., Simon, D., Bouabdallah, R., Belanger, C., Haioun, C., Thieblemont, C., Tilly, H., Harousseau, JL., Doyen, C., Martin, C., Brousse, N., & Solal-Celigny, P. (2000). High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Annals of Oncology, 11(12), 1585-1590. https://doi.org/10.1023/A:1008399623564 (Original work published 2000)